What peptide products does Thinheal supply?

Thinheal supplies generic peptide APIs, therapeutic peptides including GLP-1 and GLP-2 analogues, other gastrointestinal peptides, other therapeutic peptide APIs and cosmetic peptides, plus custom peptide R&D and CDMO manufacturing.

Does Thinheal offer custom peptide synthesis and CDMO services?

Yes. The CDMO business covers project-based contract research and development, contract manufacturing and commercial supply, from route design and process optimization to scale-up of peptide APIs and support toward formulations.

What production capacity does Thinheal have?

Thinheal operates an R&D center and a production base. Total capacity for chemically synthesized peptides has reached a multi-ton level, placing the company among the leading peptide producers in its segment.

Which quality documents can buyers request?

Buyers can request batch-specific Certificates of Analysis with HPLC purity and mass spectrometry identity data, and discuss additional documentation such as specifications, stability information and regulatory support files with the sales team for each project.

How can international buyers get the latest product catalog?

Use the Request a Catalog page or contact the regional desk for the USA and Europe, Russia and CIS, Asia, or the Middle East and East Asia by email, phone or WhatsApp.

Custom Triptorelin CAS：57773-63-4 Pricelist, Service

1 / 1

Custom Triptorelin CAS：57773-63-4 Pricelist, Service

Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist that works by acting continuously on pituitary GnRH receptors, initially stimulating and ultimately inhibiting the secretion of gonadotropins (LH, FSH), thereby reducing sex hormone (testosterone, estrogen) levels. Clinically, it is commonly used in acetate or papoate form, with sustained-release formulations (such as 1, 3, or 6-month injections) to achieve continuous action.

Send Inquiry

Product Description

Therapeutic Areas

Oncology

Prostate cancer: First-line endocrine therapy for advanced, metastatic, or locally high-risk prostate cancer, inhibiting tumor growth by lowering testosterone to castration levels.
Breast cancer: Used for ovarian function suppression in premenopausal hormone receptor-positive breast cancer, in combination with other drugs to lower estrogen levels.

Gynecology & Reproductive Medicine

Endometriosis: Relieves pain and inhibits lesion progression.
Uterine fibroids: Preoperative reduction of fibroid size can decrease surgical difficulty and bleeding.
Central precocious puberty: Inhibits premature puberty development and improves adult height prognosis.
Assisted reproductive technology (ART): Used for pituitary downregulation before controlled ovarian hyperstimulation (COS).

Other Fields

Sex-changing hormone therapy: As an initial treatment in the process of male-to-female transformation, it suppresses testosterone secretion.
Benign prostatic hyperplasia (BPH): Used for temporary relief of severe symptoms (the risk to bone health should be weighed for long-term use).

Outlook & Development

Market & Clinical Needs

The continued rise in the incidence of prostate and breast cancer, along with the demand for precision medicine in the field of reproductive health, supports the long-term market growth of Triptorelin.
Long-acting formulations (such as 6-month formulations) improve patient compliance and have become the current mainstream development direction.

Formulation & Delivery

Sustained-release technologies: Microspheres and implants extend the dosing interval and reduce adverse reactions at the injection site.
Combination therapy: Combined with novel endocrine drugs (such as androgen receptor antagonists) or targeted drugs to enhance anti-tumor effects.

Expanded Indications

Explore potential applications in ovarian cancer and pituitary hormone-related diseases.
By screening for individuals with specific health benefits through genetic testing or biomarkers, treatment strategies can be optimized.

Generics & Cost Control

After patents expire, competition from generic drugs intensifies, driving down healthcare system costs and improving drug accessibility.
Penetration in emerging markets (such as Asia and Latin America) further expands patient coverage.

Challenges & Responses

Side effect management: Decreased bone density, hot flashes, cardiovascular risks, etc., require enhanced monitoring and the development of mitigation strategies (such as combined osteoprotective agents).
Drug resistance issue: Some prostate cancer patients eventually progress to castration-resistant prostate cancer (CRPC), requiring exploration of sequential or combination therapies.

Conclusion

Triptorelin, a classic GnRH agonist, holds a solid position in oncology and reproductive endocrine disorders. Future development, through dosage form optimization, combination therapies, and expanded indications, is expected to further enhance its clinical value. Meanwhile, the widespread availability of generic versions will promote its rational use globally. Research and development will focus on balancing efficacy and long-term safety, and addressing unmet needs such as drug resistance.

Frequently Asked Questions

What is Triptorelin and how does it function?

Triptorelin is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) agonist. It continuously stimulates pituitary GnRH receptors, which ultimately leads to the suppression of gonadotropins (LH and FSH), resulting in reduced sex hormones such as testosterone and estrogen.

What are the primary oncological uses of Triptorelin?

It is primarily utilized as a first-line endocrine treatment for advanced or metastatic prostate cancer by lowering testosterone levels, and for ovarian function suppression in premenopausal hormone receptor-positive breast cancer.

Which gynecological conditions can be treated with Triptorelin?

In gynecology, it is used to manage endometriosis symptoms, shrink uterine fibroids prior to surgery, suppress pituitary function in assisted reproductive technology (ART), and treat central precocious puberty.

What are the common formulation types available?

Clinically, Triptorelin is primarily formulated as an acetate or pamoate salt in sustained-release injections designed for 1-month, 3-month, or 6-month continuous action.

What challenges are associated with long-term Triptorelin treatment?

Key clinical challenges include managing side effects such as decreased bone mineral density, hot flashes, and cardiovascular risks, as well as handling drug resistance when prostate cancer evolves into castration-resistant prostate cancer (CRPC).